Chiome Bioscience Inc.
4583.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥1 | ¥1 | ¥1 | ¥1 |
| % Growth | 14.4% | 8.2% | -11.5% | – |
| Cost of Goods Sold | ¥0 | ¥0 | ¥0 | ¥0 |
| Gross Profit | ¥0 | ¥0 | ¥0 | ¥0 |
| % Margin | 55.4% | 58.4% | 55.3% | 59.3% |
| R&D Expenses | ¥1 | ¥1 | ¥1 | ¥1 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥1 | ¥1 | ¥0 | ¥0 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥1 | ¥2 | ¥2 | ¥2 |
| Operating Income | -¥1 | -¥1 | -¥1 | -¥1 |
| % Margin | -132% | -176.6% | -199.5% | -187.2% |
| Other Income/Exp. Net | ¥0 | -¥0 | ¥0 | -¥0 |
| Pre-Tax Income | -¥1 | -¥1 | -¥1 | -¥1 |
| Tax Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Net Income | -¥1 | -¥1 | -¥1 | -¥1 |
| % Margin | -130.7% | -178.8% | -197% | -207.6% |
| EPS | -17.54 | -24.62 | -28.26 | -36.74 |
| % Growth | 28.8% | 12.9% | 23.1% | – |
| EPS Diluted | -17.54 | -24.62 | -28.26 | -36.74 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥0 | ¥0 | ¥0 | ¥0 |
| EBITDA | -¥1 | -¥1 | -¥1 | -¥1 |
| % Margin | -129.8% | -177.6% | -195.8% | -205.1% |